Beeline Medicines — Valuation, Funding & Investors

We're still building this profile — here is what Pulse has covered.

Latest Pulse

Jul 1, 2026Bain, CPP and Bristol Myers Add $126M to Beeline's Lupus PipelineBeeline Medicines closed a $126.3 million Series A extension from Bain Capital, CPP Investments and Bristol Myers Squibb, upsizing its total Series A to $426.3 million to fund pivotal development of afimetoran in lupus ahead of a Phase 2 readout expected in.→

Coverage Timeline

newest first

Jul 1, 2026FUNDINGBain, CPP and Bristol Myers Add $126M to Beeline's Lupus Pipeline$126.3M Series A extension→

All Coverage

FUNDING· Jul 1, 2026

Bain, CPP and Bristol Myers Add $126M to Beeline's Lupus Pipeline

FUNDING$126.3M Series A extension

Bain, CPP and Bristol Myers Add $126M to Beeline's Lupus Pipeline

Beeline Medicines closed a $126.3 million Series A extension from Bain Capital, CPP Investments and Bristol Myers Squibb, upsizing its total Series A to $426.3 million to fund pivotal development of afimetoran in lupus ahead of a Phase 2 readout expected in.

Jul 1, 2026

Related Companies

Same sector

Attovia Therapeutics Apnimed Braveheart Bio Latigo Biotherapeutics Scribe Therapeutics